Sildenafil Tablet, Film Coated
Product Images NDC 71335-0969

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 71335-0969). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl713350969)

Label for Sildenafil Citrate 100 mg tablets, film coated, packaged by Bryant Ranch Prepack in Burbank, CA. The label states it is comparable to Viagra 100 mg tablets by Amneal Pharmaceuticals Pvt Ltd. It includes storage instructions (store at 20°-25°C) and a warning to keep drugs out of reach of children. The NDC is 71335-0969-1.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 1)

Chemical structure diagram of sildenafil, the active ingredient in the drug product labeled Sildenafil 100 mg tablet, film coated by Bryant Ranch Prepack. The diagram shows the molecular arrangement including atom connectivity and typical chemical notation.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 2)

A line graph comparing systolic blood pressure (mmHg) over time post dose (hours) between Sildenafil 100 mg and placebo groups. The x-axis represents time from pre-dose to 24 hours, and the y-axis shows changes in systolic blood pressure values. Two lines track blood pressure changes for Sildenafil and placebo subjects throughout the 24-hour period.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 3)

A line graph showing change in systolic blood pressure (SBP) in mmHg over time post dose in hours. Two data series compare Doxazosin + Placebo and Doxazosin + Sildenafil 25 mg. The x-axis represents time post dose (0 to 8 hours), and the y-axis represents change in SBP, ranging approximately from -40 to 20 mmHg, illustrating blood pressure trends following treatment.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 4)

A line graph showing change in systolic blood pressure (SBP) in mmHg over time in hours post dose. Two data series compare Doxazosin + Placebo versus Doxazosin + Sildenafil 50 mg, illustrating the blood pressure changes following administration.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 5)

A line graph comparing the effects of Doxazosin combined with Sildenafil 100 mg versus Doxazosin combined with Placebo on mmHg (blood pressure) over 8 hours after dosing. Two lines represent the two treatments, showing changes in mmHg values across the time points.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 6)

A line graph showing plasma concentrations of Sildenafil (ng/ml) over time post dose (hours) after administration of a commercial tablet. The graph illustrates the concentration peaking shortly after dosing and subsequently declining over a 24-hour period.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 7)

A bar chart titled 'Effect of sildenafil on Maintenance of Erection by Baseline Score' showing the percentage of patients at endpoint across baseline scores from 0 to 5. Multiple bars per baseline score represent different categories labeled 0 through 5, with increasing percentages observed for higher categories, especially category 5.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 8)

A bar chart titled 'Effect of Placebo on Maintenance of Erection by Baseline Score' showing the percentage of patients at endpoint on the vertical axis and baseline scores on the horizontal axis from 0 to 5. Multiple bars represent different subgroups (0 to 5) within each baseline score category, illustrating variations in patient response to placebo across baseline scores.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 9)

Bar chart showing the percentage of patients reporting improvement by treatment group. The groups are Placebo (24%, n=463), Sildenafil 25 mg (63%, n=214), Sildenafil 50 mg (74%, n=391), and Sildenafil 100 mg (82%, n=380). The overall treatment significance is indicated as p < 0.0001.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.